Exchange: NASDAQ·Updated 08:52 AM EDT
News
all
press releases
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday's regular session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC) stock roseread more...
Benzinga
More News
Catalysts Put These Companies in the Spotlight
ClearOne (NASDAQ CLRO), NeOnc Technologies (NASDAQ:NTHI), Iovance Biotherapeutics (NASDAQ:IOVA), and Ensysce Biosciences (NASDAQ:ENSC) are covered in today’s roundup.
24-7 Market News
Ensysce Lands Up to $77 Million to Fuel Next Generation Pain Therapy Pipeline
Ensysce Biosciences (NASDAQ: ENSC) has taken a significant strategic step toward becoming a broader pain therapeutics company with the acquisition of clinical-stage Cy Biopharma, bringing together two distinct approaches to addressing one of healthcare's largest unmet needs. The transaction is backed by up to $77 million in financing and positions the combined company to advance both a next-generation non-opioid pain therapy and Ensysce's proprietary abuse-resistant opioid platform.
24-7 Market News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 55.4% to $0.44 during Tuesday's pre-market session. The company's market cap stands at $4.3 million. Adagio Medical Holdings (NASDAQ:ADGM) stockread more...
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock rose 118.1% to $0.61 during Monday's after-market session. The market value of their outstanding shares is at $3.8 million. TransCode Therapeutics (NASDAQ:RNAZ)read more...
Benzinga
Top Penny Stocks To Follow Today - February 27th
OneMedNet, Ensysce Biosciences, and Banco Bradesco are the three Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are low-priced shares of small companies that...
MarketBeat
Tiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic Review
Ensysce Biosciences stock surged 58% after launching a strategic review to explore partnerships, licensing deals, or asset sales.read more...
Benzinga
Ensysce Biosciences Stock Rises On Positive Data From Opioid Overdose Protection Study: Retail’s Thrilled
The company stated that a 100 mg dosage of PF614-MPAR delivers oxycodone to treat severe pain and provides overdose protection when a greater-than-prescribed dose is consumed.
Stocktwits

Advertisement|Remove ads.